IntegriChain Appoints New Chief Revenue Officer
The commercialization platform seeks to drive growth as it enters its 20th year of operations.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Do you believe hiring external executives is the best way for established companies to grow?
IntegriChain has appointed Chris Hare as its new chief revenue officer to oversee commercial growth. The Philadelphia-based company, which operates a platform for drug access and profitability, currently employs more than 700 people.
Why it matters
The executive hire marks a strategic leadership move for IntegriChain, a company now in its 20th year and backed by private equity firm Nordic Capital. Hare brings experience from prior roles in medical systems and health technology growth, signaling a focus on scaling operations.
IntegriChain enters its 20th year of business with a workforce of over 700 employees. The company functions as a portfolio firm under Nordic Capital, which acquired a majority share of the business in November 2023.
The players
IntegriChain
A Philadelphia-based technology firm providing commercialization and consulting services for drug access and financial operations.
Chris Hare
The new chief revenue officer at IntegriChain with a track record of growth leadership at Intelerad Medical Systems and Net Health.
Nordic Capital
A private equity firm that acquired a majority interest in IntegriChain to support its strategic scaling.
Intelerad Medical Systems
A medical imaging software provider that was acquired by GE Healthcare in a $2.3 billion transaction.
The details
IntegriChain provides a commercialization platform that integrates financial and operational data for drug access. As chief revenue officer, Hare is expected to apply his background in health systems to the company's consulting and software services in government pricing and product channel distribution. He previously spent over two years at Intelerad Medical Systems, which was sold to GE Healthcare for $2.3 billion in April 2026.
Timeline
November 2023: Nordic Capital acquired a majority stake in IntegriChain.
April 2026: Intelerad Medical Systems was sold to GE Healthcare for $2.3 billion.
October 2026: IntegriChain hired Chris Hare as its new chief revenue officer.
Market Landscape
The hiring of Hare follows a pattern set by the April 2026 acquisition of Intelerad Medical Systems by GE Healthcare, where executive talent moves between rapidly scaling health-tech entities. IntegriChain continues to operate within the competitive drug commercialization sector as a Nordic Capital portfolio company.
Operators in the pharmaceutical and life sciences sectors should monitor how IntegriChain alters its consulting services under this new commercial leadership. Increased focus on revenue growth could signal changes in how the company structures its channel and distribution support contracts.
The takeaway
IntegriChain is leveraging executive experience from high-value exits to refine its commercialization platform. Competitors should track whether the company shifts its pricing strategy or service bundle offerings to capture more market share in the drug access consulting space.
Further reading
For more on industry leadership changes, visit Healthcare.
Source note: This article includes information reported by Consulting.
Live Poll
Do you believe hiring external executives is the best way for established companies to grow?
